Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Russ McMahen"'
Publikováno v:
Clinical Therapeutics. 39:2389-2398
Purpose A new amphetamine extended-release liquid formulation (AMP XR-OS), intended for the treatment of attention-deficit/hyperactivity disorder, has been developed. This study was performed to determine if administration with food affected the rate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb6067d5c08c89faffaeb703734629b2
https://doi.org/10.1016/j.clinthera.2017.10.018
https://doi.org/10.1016/j.clinthera.2017.10.018
Publikováno v:
Journal of Attention Disorders. 24:414-419
Objective: The purpose of this study was to compare the pharmacokinetics of a new extended-release amphetamine oral suspension (AMP XR-OS) with a standard extended-release mixed amphetamine salts product, Adderall XR®. Method: In this single-dose, o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40f1aaae91744cf61e3fccece5a7ed8b
https://doi.org/10.1177/1087054717743329
https://doi.org/10.1177/1087054717743329
Publikováno v:
Clinical Therapeutics. 39:1695-1705
Purpose There is a strong association between attention-deficit/hyperactivity disorder (ADHD) and alcohol abuse, yet no studies have systematically assessed the effect of alcohol on the pharmacokinetics of psychostimulants such as amphetamine (AMP) i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61b97bb9f395a7c14faf0a661af2c502
https://doi.org/10.1016/j.clinthera.2017.07.006
https://doi.org/10.1016/j.clinthera.2017.07.006
Autor:
Mark Tengler, Jeffrey H. Newcorn, Jeffrey G. Stark, Russ McMahen, Carolyn Sikes, Ann C. Childress
Publikováno v:
Journal of Child and Adolescent Psychopharmacology
Objective: To determine the pharmacokinetic (PK) profile of a proprietary formulation of methylphenidate (MPH) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) in a phase 1 study. Methylphenidate extended-release orall
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b86a9247be5f43bbfb65f9699f6a1a2e
http://europepmc.org/articles/PMC4991613
http://europepmc.org/articles/PMC4991613
Publikováno v:
Journal of clinical psychopharmacology. 38(5)
A methylphenidate (MPH) extended-release orally disintegrating tablet (MPH XR-ODT) formulation was recently approved for attention-deficit/hyperactivity disorder treatment in children 6 to 17 years of age. This analysis sought to develop a population
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b15185c62f116a3c7edb29932d94d26a
https://pubmed.ncbi.nlm.nih.gov/30119076
https://pubmed.ncbi.nlm.nih.gov/30119076
Publikováno v:
Journal of child and adolescent psychopharmacology. 28(8)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c341a4fecf66b527ed9bf3076ff7319
https://pubmed.ncbi.nlm.nih.gov/30085849
https://pubmed.ncbi.nlm.nih.gov/30085849
Publikováno v:
Journal of child and adolescent psychopharmacology. 28(1)
An extended-release amphetamine (AMP) oral suspension has been developed to facilitate medication ingestion and dose titration. This study sought to determine the pharmacokinetic (PK) profile of this new formulation in children with attention-deficit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::121f830022d9bd83bdd8bac528524a9e
https://pubmed.ncbi.nlm.nih.gov/28933918
https://pubmed.ncbi.nlm.nih.gov/28933918
Publikováno v:
Journal of child and adolescent psychopharmacology. 27(3)
Background: A novel formulation for treating attention-deficit/hyperactivity disorder (ADHD) has recently been developed—amphetamine extended-release orally disintegrating tablets (AMP XR-ODTs). In this study, we assessed the rate of absorption and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb1cafdd1c22597f875574ef37df9cdc
https://pubmed.ncbi.nlm.nih.gov/27936898
https://pubmed.ncbi.nlm.nih.gov/27936898
Publikováno v:
Clinical pharmacology in drug development. 7(2)
Extended-release (ER) methylphenidate (MPH) is a first-line treatment for attention-deficit/hyperactivity disorder. A methylphenidate extended-release orally disintegrating tablet (MPH XR-ODT) has recently been developed. This was a randomized, open-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7b0b276929a14bb4a841f009061518e
https://pubmed.ncbi.nlm.nih.gov/28544581
https://pubmed.ncbi.nlm.nih.gov/28544581
Publikováno v:
Postgraduate medicine. 128(7)
In this pharmacokinetic (PK) study in healthy adults, we sought to: (1) compare the PK properties of a novel amphetamine extended-release orally disintegrating tablet formulation (Adzenys XR-ODT™ [AMP XR-ODT]) to a reference extended-release mixed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa9072c031f9398b11f2a0325347c4bd
https://pubmed.ncbi.nlm.nih.gov/27488574
https://pubmed.ncbi.nlm.nih.gov/27488574